The final stage of testing for India's homegrown dengue vaccine has begun.
Every year, dengue fever puts millions of Indian families in peril, with children being the most vulnerable.
With no licensed vaccine available in India, the country has been fighting dengue with one hand tied behind its back.
Enter DengiAll: A 'Made in India' single-shot vaccine developed by Panacea Biotec to fight all four dengue strains.
The crucial Phase-3 clinical trial has launched across India’s top medical research centers.
From Pune and Kolkata to Delhi and Chennai, 20 trial sites are now active in this historic fight.
Over ten thousand brave volunteers, aged 18-80, are participating in this landmark two-year study.
To ensure unbiased results, neither the volunteers nor the scientists know who is receiving the vaccine or a placebo.
Earlier Phase 1 and 2 trials have already shown the vaccine to be safe, paving the way for this final test.
DengiAll is a tetravalent vaccine, meaning one single dose is engineered to protect against all four types of the dengue virus.
Volunteers will be closely monitored for the next two years to measure long-term safety and immunity.
Final results are expected after October. If successful, the vaccine could be approved for use as early as 2026.
A successful trial could finally end the reign of fear that dengue has held over India for decades.